Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.28) per share for the quarter.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.32). During the same period in the prior year, the company posted ($1.00) earnings per share. On average, analysts expect Eledon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ ELDN traded up $0.03 during mid-day trading on Friday, hitting $3.31. The company's stock had a trading volume of 96,113 shares, compared to its average volume of 285,376. Eledon Pharmaceuticals has a one year low of $2.00 and a one year high of $5.54. The company's fifty day simple moving average is $3.37 and its 200-day simple moving average is $3.98. The stock has a market cap of $198.21 million, a price-to-earnings ratio of -1.65 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a "buy" rating and a $9.00 target price on the stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).